Detection of Azole Drug Resistance of the Aspergillus Species Cyp51a Gene by PCR

Raksha¹, Gurjeet Singh¹, A D Urhekar²

ABSTRACT
Background: Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity pulmonary disease occurring in individuals with asthma or cystic fibrosis. In these patients, it is characterized by transient pulmonary infiltrates, reversible airway obstruction, eosinophilia, and evidence of hypersensitivity to the Aspergillus fumigatus. The aim of this study was standardization of antifungal drug susceptibility testing genotypic methods.

Materials and Methods: This prospective and experimental study was carried out at the Department of Microbiology and Central Research Laboratory, Mahatma Gandhi Mission Medical College and Hospital, Navi Mumbai, and gene sequencing was carried out at Eurofins Laboratory. A molecular method for standardization of drug sensitivity testing for azole drug was done using Cyp51A gene and mutation M220 and L98H. The American Type Culture Collection control strain of Aspergillus oryzae, Aspergillus niger, and Aspergillus brasiliensis was obtained from Microbiologics Inc., USA.

Results: Azole drug resistance by polymerase chain reaction (PCR) revealed 48/60 (80%), and azole drug resistance showed L98H and M220 genes in 32/60 (60%). Gene sequencing of Aspergillus species in patient samples revealed M220 and L98H mutation in cyp51A gene of Aspergillus Species.

Conclusion: Azole drug resistance by PCR showed L98H and M220 in cyp51A gene. Gene sequencing showed similar resistance by PCR.

KEY WORDS: Azole, polymerase chain reaction, gene sequencing, cyp51A.

Introduction
Allergic aspergillosis is a hypersensitivity disease manifesting in several clinical forms, including allergic susceptible bronchopulmonary aspergillosis allergic bronchopulmonary aspergillosis (ABPA). ABPA is described by bronchiectasis, wheezing, pulmonary infiltrates, and sputum containing brown plugs. Asthmatic and cystic fibrosis patients are primarily at risk. As ABPA is a long-term condition, its prevalence is higher than invasive aspergillosis (IA), but its annual incidence or rate of new diagnoses is probably lower. In addition to the conventional corticosteroid treatment, itraconazole (ITC) antifungal therapy has been shown to be advantageous in 60% of cases.
Intrusive aspergillosis IA has risen as a perilous contamination in immunocompromised patients. An expansion in contaminations due toazole-safe A. fumigatus has been watched lately,[13-15] prompting a higher case casualty rate among patients withazole-safe obtrusive aspergillosis.[16] The rule obtained or watched segment giving azole sedate obstacle entangles point changes in the 14-sterol demethylase quality (cyp51A) just as extended cyp51A verbalization due to a couple repeat (TR) sponsor modification.[5,17-20] As yet, the recognizable proof of assurance from azoles (itraconazole, voriconazole, posaconazole) is totally established on positive social orders from clinical isolates, and the to this point existing PCR measures to recognize both the azole restriction mediating pair repeat and the single nucleotide polymorphisms were performed with culture tests and depend upon positive culture disclosures from clinical segregates.[17,18,21-23] Up to now, just a single PCR-based measure that distinguishes cyp51A transformations straightforwardly in clinical examples (sputum) from patients with pneumonia ailments such as hypersensitive bronchopulmonary aspergillosis ABPA and ceaseless aspiratory aspergillosis has been depicted. In this investigation, tests from a couple of patients experiencing obtrusive pneumonia aspergillosis invasive pulmonary aspergillosis were additionally tried, yet these examples did not yield results due to a deficient measure of test remaining.[24] From a clinical perspective, in any event in patients with hematological malignancies at high hazard for IA, apparent Aspergillus culture yields are rare and a culture-based determination of IA is once in a while achieved.[25,26]

**Materials and Methods**

This prospective, molecular, and experimental study was conducted at Microbiology Laboratory and Central Research Laboratory, Mahatma Gandhi Mission Medical College and Hospital, Navi Mumbai, Maharashtra, India. Gene sequencing was done at Eurofins Laboratory, Bengaluru, with Head Office in the UK.

**Primer sequences**

The oligonucleotide primers used in this study are described in Table 1. The primers were obtained from Sigma, USA.

**PCR specification**

PCR amplifications were performed in accordance to a procedure as followed by Spiess et al.[27] According to the procedure Master Mix “GoTaq Green Master Mix” (Promega Bio Sciences, LLC., USA), 5 µl DNA, 20 pmol of primers were added and mixed to obtain 50 µl final volume of the PCR mix.

**Reaction conditions**

Cycling conditions of first and nested-step PCR reactions was performed according to previously published work.[27] The reaction and the cycling condition in PCR were followed step by step, i.e. firstly initial denaturation of the DNA occurred at 94°C for 2 min, followed by 40 cycles, then again denaturation occurs at 94°C for 45 s, annealing at 52°C for 1 min then extension at 72°C for 1 min and final extension at 72°C for 10 min (Table 2).

**Agarose gel electrophoresis:**

The PCR products along with the appropriate ladder (Bioline, India) were subjected to electrophoresis in a 1.5% agarose gel using 1 X Tris Acetate EDTA (TAE) buffer. The presence of band of the L98H and M220 in Cyp51A gene in gel electrophoresis confers to Azole drug resistance (Figures 1 and 2).

**Gene sequencing**

Gene sequencing of amplified product was done using Sanger method (BigDye Terminator chemistry, gel: Pop 7 polymer) 3730XL DNA Analyzer (Applied Biosystems®).

**Cycle sequencing**

Australian Genome Research Facility (AGRF) cycling conditions for PD sequencing service was performed according to the Table 3. The temperature and time and the number of cycles condition were followed step

---

**Table 1: Primers used to amplify azole drug-resistant gene fragments**

| Mutation name | Primer     | Orientation | Nucleotide sequence (5’–3’) | Fragment length (bp) | Gene code     |
|---------------|------------|-------------|-----------------------------|----------------------|---------------|
| L98H mutation| CypA-L98H-S_A | Sense       | AAAAAACCACAGTCTACCTGG       | 143                  | KP270768.1    |
|              | CypA-L98H-AS_A | Antisense   | GGAATTGGGACAATCATACAC       |                      | KP270768.1    |
| M220 mutation| CypA-M220-S_A | Sense       | GCCAGGAAGTTCGTTCCAA         | 173                  | KP270768.1    |
|              | CypA-M220-AS_A | Antisense   | CTGATTTGATGATGTCACAGTA      |                      | KP270768.1    |
Detection of azole drug resistance of the Aspergillus species Cyp51a gene by PCR

Results
The present examination was directed for recognizing azole tranquilizes safe transformations in Aspergillus species. A total of 60 isolates were included in this study out of that 80% was L98H gene and 60% M220 genes (Table 4).

Detection of L98H and M220 mutations in cyp51A gene of Aspergillus species was done by polymerase chain reaction (PCR).

Sequence analysis of L98H and M220 in cyp51A gene
The nested PCR products of L98H and M220 in cyp51A gene from the above samples were directly sequenced.

Table 2: Cycling conditions of first and nested step PCR reactions

| Reaction | Cycling condition |
|----------|-------------------|
| Initial denaturation | 94°C for 2 min followed by 40 cycles |
| Denaturation | 94°C for 45 s |
| Annealing | 52°C for 1 min |
| Extension | 72°C for 1 min |
| Final extension | 72°C for 10 min |

PCR: Polymerase chain reaction

Table 3: Showing Australian Genome Research Facility cycling conditions for PD sequencing service

| Temperature and time | Number of cycles |
|----------------------|------------------|
| 95°C for 2 min       | 1                |
| 95°C for 30 s        | 30               |
| 55°C for 30 s        |                  |
| 60°C for 4 min       |                  |
| 4°C                  | Hold             |

PCR: Polymerase chain reaction

Table 4: Detection of drug resistance genes of Aspergillus species by PCR

| Number of samples tested | L98H (%) | M220 (%) |
|--------------------------|----------|----------|
| Isolates (n=60)          | 48 (80)  | 36 (60)  |

PCR: Polymerase chain reaction

Table 5: Drug sensitivity pattern of Aspergillus species

| Sample | In vitro drug sensitivity status | cyp51A gene | L98H | No mutation |
|--------|----------------------------------|-------------|------|-------------|
| Isolates (n=60) | Azole Resistant Strain (n=60) |             | 48   | 12          |

by step, i.e. at 95°C for 2 min and the number of cycle was one, at 95°C for 30 s and 55°C for 30 s, the number of cycle were 30 for each and hold at 4°C (Table 3).
sequenced in both directions, using an 3730XL DNA sequence (Sanger method, BigDye Terminator chemistry and Pop 7 polymer gel) from Eurofins IT Solutions India Pvt. Ltd. (Bengaluru, India). Total 60 isolates which were resistant to azole drug were further confirmed by gene sequencing analysing using Sanger method, out of which 48 isolates were confirmed with L98H mutation whereas 12 isolates showed no L98H mutation (Table 5, and Figure 3) and 36 isolates were confirmed with M220 genes however 24 isolates showed no M220 mutation (Table 6, and Figure 4).

**Discussion**

In this chapter, drug resistance pattern of azole was studied in *Aspergillus* isolates by PCR and azole drug resistance mutations were studied by gene sequencing.

Cyp51A–L98H-S Aa/Ab and Cyp51A-M220-SA/AS-A primers were used in the study. The study was done on 60 *Aspergillus* isolates.

About 48/60 (80%) *Aspergillus* isolates showed the presence of L98H, whereas 32/60 (60%) showed M220 azole drug resistance mutant genes.

| Sample | In vitro drug sensitivity status | cyp51A gene mutation |
|--------|---------------------------------|----------------------|
| Isolates (n=60) | Azole Resistant strain (n=60) | M220 | No. mutation |
| | | 36 | 24 |

**Table 6: Azole drug sensitivity of Aspergillus species**

In vitro drug sensitivity of 60 *Aspergillus* isolates revealed 48 azole resistance strains and 12 azole-sensitive strains. All 48 azole drug resistance strains showed Cyp51A (L98H) mutation, whereas 12 strains did not show mutation and drug resistance.

Thirty-two azole resistance strains showed M220 mutation, where in 28 strains, no mutation was observed.

Gene sequencing revealed (TTC→TTT) mutation in L98H mutant genes and (CGC→CGT) in M220 mutant genes (Figures 5 and 6).

Our results correlate with Bueid *et al.*[13](#) who reported that 78% of cases have multi-azole drug resistance.

In assurance of the opposition system in Cyp51A quality toward ITC, succession examination and level Cyp51A quality articulation were contemplated. Preliminary sets were chosen for Cyp51A quality enhancement dependent on past examinations. In light of arrangement examination, *A. fumigatus* disengages C21, C53, M310, M2470, and UZ291 demonstrated the nearness of L98H transformation. In the meantime, M220 change was distinguished in UZ165 confine, and both L98H and M220 transformations were identified in UZ23 and UZ685 disengages. The pair rehash TR change was resolved dependent on the amplicon estimate (100 bp), and this transformation was not recognized as there was no expansion of 34 bp in the amplicons.[12]

In light of past research,[13](#) the cross-obstruction toward azole drugs is identified with articulation dimension of Cyp51A quality which is because of a Tandem Repeat 34 bp in the advertiser locale and amino corrosive changes at area 98 leucine (TRL98H). The L98H, M220, and Tandem Repeat were not recognized at all in *Aspergillus niger* confines, and the opposition in *A. niger* might be due to different elements.[6](#) In the meantime, the
opposition segregates which do not demonstrate any quality articulation or L98H, M220, and TR change could be due to the essence of different transformations, for example, F46Y, G89G, M172V, N248 T, D255E, L358 L, E427K, C454C, L358 L, or efflux siphon component.[14]

While the dimension of Cyp51A quality articulation is higher particularly in safe A. niger segregates, this expansion is not huge. The G427S transformation was recognized in M046, M407 and M1772 separates of A. niger which may show a critical connection with Itraconazole antifungal medication opposition. Anyway it was unrealistic to enhance alternate disconnects with the preliminary pair utilized. This is on the grounds that A. niger is an animal groups complex comprising of various distinctive strains[12] and a few other preliminary sets would need to be utilized so as to enhance alternate disconnects.[28,29]

Conclusion
In our study, we found that molecular method is time-effective method giving results within short time required for the test and identification of azole drug resistance, which help doctor to regulate proper antifungal drugs and minimize morbidity and mortality of patients suffering from IA. Mutations such as L98H and M220 in gene cyp51A are very helpful biomarkers for the identification of azole mediate obstruction in aspergillus patients.

References
1. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, et al. Practice guidelines for diseases caused by aspergillus. Infectious diseases society of America. Clin Infect Dis 2000;30:696-709.
2. Moss RB. Pathophysiology and immunology of allergic bronchopulmonary aspergillosis. Med Mycol 2005; 43 Suppl 1:S203-6.
3. Denning DW, O’Driscoll BR, Hogaboam CM, Bowyer P, Niven RM. The link between fungi and severe asthma: A summary of the evidence. Eur Respir J 2006;27:615-26.
4. Pepsy J, Riddell RW, Citron KM, Clayton YM, Short EI, Bowyer P, et al. Clinical and immunologic significance of Aspergillus fumigatus in the sputum. Am Rev Respir Dis 1995;152:167-70.
5. Machmeyer G, Haas A, Cornely OA. Invasive aspergillosis: Epidemiology, diagnosis and management in immunocompromised patients. Drugs 2007;67:1567-601.
6. Kramer MR, Denning DW, Marshall SE, Ross DJ, Berry G, Lewiston NJ, et al. Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis 1991;144:552-6.
7. Westney GE, Kesten S, De Hoyos A, Chapparro C, Winton T, Maurer JR, et al. Aspergillus infection in single and double lung transplant recipients. Transplantation 1996;61:915-9.
8. Gomez-Lopez A, Garcia-Effron G, Mellado E, Monzon A, Rodriguez-Tudela JL, Cuenca-Estrella M. In vitro activities of three licensed antifungal agents against Spanish clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2003;47:3085-8.
9. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol 2008 46:2568-72.
10. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varqa J, Samson R, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008;5:e219.
11. Mellado E, Alcazar-Fuoli L, Garcia-Effron G, Alastuey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. New resistance mechanisms toazole drugs in Aspergillus fumigatus and emergence of antifungal drugs-resistant A. fumigatus atypical strains. Med Mycol 2006;44:367-71.
12. Howard SJ, Webster I, Moore CB, Gardiner RE, Park S, Perlin DS, et al. Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents 2006;28:450-3.
13. Bueid A, Howard SJ, Moore CB, Richardson MD, Harrison E, Bowyer P, et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother 2010; 65:2116-8.
14. Howard SJ, Arendrup MC. Acquired antifungal drug resistance in Aspergillus fumigatus: Epidemiology and detection. Med Mycol 2011;49 Suppl 1:S90-5.
15. Verweij PE, Howard SJ, Melchers WJ, Denning DW. Azole-resistance in aspergillus: Proposed nomenclature and breakpoints. Drug Resist Update 2009;12:141-7.
16. Van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, Debes-Ossenkopp YJ, et al. Clinical implications ofazole resistance in Aspergillus fumigatus, the Netherlands, 2007-2009. Emerg Infect Dis 2011;17:1846-54.
17. Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Rodriguez-Tudela JL. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2003;47:1120-4.
18. Mellado E, Garcia-Effron G, Alcázar-Fuoli L, Melchers WJ, Verweij PE, Cuenca-Estrella M, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007;51:1897-904.
19. Perlin DS. Antifungal drug resistance: Do molecular methods provide a way forward? Curr Opin Infect Dis 2009;22:568-73.
20. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in Aspergillus fumigatus: A side-effect of environmental fungicide use? Lancet Infect Dis 2009;9:789-95.
21. Garcia-Effron G, Dilger A, Alcazar-Fuoli L, Park S, Mellado E, Perlin DS, et al. Rapid detection of triazole antifungal resistance in Aspergillus fumigatus. J Clin Microbiol 2008;46:1200-6.
22. Klaassen CH, de Valk HA, Curfs-Breuker IM, Meis JF. Novel mixed-format real-time PCR assay to detect mutations conferring resistance to triazoles in Aspergillus fumigatus and prevalence of multi-triazole resistance among clinical isolates in the Netherlands. J Antimicrob Chemother 2010; 65:901-5.
23. van der Linden JW, Jansen RR, Bresters D, Visser CE, Geerlings SE, Kuijper EJ, et al. Azole-resistant central nervous system aspergillosis. Clin Infect Dis 2009;48:1111-3.
24. Denning DW, Park S, Lass-Florl C, Fraczek MG, Kirwan M,
Gore R, et al. High-frequency triazole resistance found in nonculturable *Aspergillus fumigatus* from lungs of patients with chronic fungal disease. Clin Infect Dis 2011;52:1123-9.

25. Ruhnke M, Böhme A, Buchheidt D, Cornely O, Donhuijsen K, Einsele H, et al. Diagnosis of invasive fungal infections in hematology and oncology guidelines from the infectious diseases working party in haematology and oncology of the german society for haematology and oncology (AGIHO). Ann Oncol 2012;23:823-33.

26. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: Clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis 2008;46:327-60.

27. Spiess B, Seifarth W, Merker N, Howard SJ, Reinwald M, Dietz A, et al. Development of novel PCR assays to detect azole resistance-mediating mutations of the *Aspergillus fumigatus* cyp51A gene in primary clinical samples from neutropenic patients. Antimicrob Agents Chemother 2012; 56:3905-10.

28. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998;26:781-803.

29. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, et al. Frequency and evolution of azole resistance in *Aspergillus fumigatus* associated with treatment failure. Emerg Infect Dis 2009;15:1068-76.

Financial Support: None; Conflict of Interest: None

How to cite this article: Raksha, Singh G, Urhekar AD. Detection of Azole Drug Resistance of the *Aspergillus* Species Cyp51a Gene by PCR. J Med Sci Health 2019;5(1):15-20.

Date of submission: 12-03-2019
Date of review: 19-04-2019
Date of acceptance: 23-04-2019
Date of publication: 10-06-2019